Thursday 7 June |
| SESSION 1: PATHOPHYSIOLOGY AND METHODOLOGY |
 |
Welcome and Introduction
R. De Caterina
Documents available:
 |
|
Atherothrombosis: Pathophysiological background
R. De Caterina Documents available:
|
 |
Old and new methods to assess platelet function and resistance to antiplatelet drugs
S.D. Kristensen
Documents available:
|
| SESSION 2: UPDATE IN PHARMACOLOGY AND DEVICES |
|
Low-dose aspirin, coxibs, NSAIDs and their combination
D. Fitzgerald
Documents available:
|
|
New antiplatelet agents
D. Moliterno
Documents available:
|
|
Coagulation 2007: sites of action of new inhibitors and monitoring
D. Moliterno
Documents available:
|
 |
Stents and devices: trading restenosis for late stent thrombosis?
G. Steg
Documents available:
|
|
PPAR-gamma agonists in atherothrombosis
R. De Caterina
Documents available:
|
|
Rimonabant
G. Steg
Documents available:
|
Friday 8 June |
| SESSION 3: NON-ST ELEVATION ACUTE CORONARY SYNDROMES |
 |
Markers for Risk Stratification
F. Andreotti
Documents available:
|
 |
Debate: Conservative strategies in NSTE-ACS - part I
F.W.A. Verheugt
Documents available:
|
 |
Debate: Invasive strategies in NSTE-ACS - part II
K. Huber
Documents available:
|
|
Debate: discussion
Documents available:
|
|
Optimal antithrombotic therapy for patients undergoing PCI - unfractionated heparin, low-molecular weight heparins, bivalirudin, GP IIb-IIIa antagonists
S.D. Kristensen
Documents available:
|
|
Clopidogrel: how much, how early, for how long? Can we skip GP IIb/IIIa antagonists?
L.H. Rasmussen
Documents available:
|
| SESSION 4: CLOPIDOGREL IN NON-STEMI, STEMI AND PCI: HOW MUCH, HOW EARLY, FOR HOW LONG, WITH OR WITHOUT GP IIB/IIIA ANTAGONISTS? |
 |
Case presentations
M. Zimarino
Documents available:
|
|
Bleeding in ACS: the difficult trade-off for thrombosis prevention
F. Andreotti
Documents available:
|
|
Triple anti-thrombotic therapy with aspirin, clopidogrel and vitamin K antagonists: rationale and risk
S. Husted
Documents available:
|
| SESSION 5: ACUTE ST-ELEVATION MYOCARDIAL INFARCTION |
|
Pre-hospital thrombosis
G. Steg
Documents available:
|
|
Organizational models for primary PCI
K. Huber
Documents available:
|
|
Cath lab therapy in STEMI
S.D. Kristensen
Documents available:
|
|
PCI facilitation: forget it - forget me not...
F.W. Verheugt
Documents available:
|
Saturday 9 June |
| SESSION 6: ATRIAL FIBRILLATION |
|
Warfarin, aspirin and clopidogrel: lessons from ACTIVE-W
R. De Caterina
Documents available:
|
|
Dabigatran, idraoarinux, oral FXa inhibitors
S. Husted
Documents available:
|
|
ACE-inhibitors and sartans in AF
L.H. Rasmussen
Documents available:
|
| SESSION 7: FUTURE DEVELOPMENTS |
|
Stem cells in cardiovascular therapy - Background biology and critical issues
J.F. Martin
Documents available:
|
|
Stem cells in cardiovascular therapy: a critical reading of clinical trials
S. Janssens
Documents available:
|
| |